Efficacy of Vorinostat

Vorinostat is a new medicine used to treat cutaneous T-cell lymphoma (CTCL) when the disease persists, worsens, or recurs during or after treatment with other medicines. It is an effective and well-tolerated drug and is considered a new treatment for this disease. Currently, in addition to cutaneous T-cell lymphoma, vorinostat is also being studied for other types of cancer, both as monotherapy and in combination.

In a study of patients with advanced cutaneous T-cell lymphoma (stage IIB and above) who received vorinostat, the primary endpoint was response rate to oral vorinostat in patients with advanced cutaneous T-cell lymphoma (stage IIB and above) who had progressive, persistent, or relapsing disease on or after two systemic therapies. The overall objective response rate was 29.7%. Among patients with stage IIB and higher CTCL, the overall objective response rate was 29.5%. One patient with stage IIB CTCL achieved CCR. The median time to response was 55 and 56 days for the overall population and for patients with stage IIB and higher CTCL, respectively. However, in rare cases, it can take up to 6 months for patients to develop an objective response to vorinostat.

The original drug of vorinostat is not currently on the market in China, and therefore cannot be included in the national medical insurance coverage. Overseas, there is an American version of the original drug, specifications100mg*120 pills per box, which may cost around 100,000 yuan (the price may fluctuate due to exchange rate effects). It is very expensive, and there is currently no generic version of vorinostat produced and launched. For more drug information and specific prices, please consult a medical consultant.